Home > Publications Database > Naphtho[1,2-b][1,4]diazepinedione-Based P2X4 Receptor Antagonists from Structure-Activity Relationship Studies toward PET Tracer Development. > print

001     277979
005     20250430100241.0
024 7 _ |a 10.1021/acs.jmedchem.4c02171
|2 doi
024 7 _ |a pmid:39805099
|2 pmid
024 7 _ |a 0095-9065
|2 ISSN
024 7 _ |a 0022-2623
|2 ISSN
024 7 _ |a 1520-4804
|2 ISSN
024 7 _ |a 1943-2992
|2 ISSN
037 _ _ |a DZNE-2025-00511
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Erlitz, Katharina Sophie
|b 0
245 _ _ |a Naphtho[1,2-b][1,4]diazepinedione-Based P2X4 Receptor Antagonists from Structure-Activity Relationship Studies toward PET Tracer Development.
260 _ _ |a Washington, DC
|c 2025
|b ACS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1745916868_20011
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The P2X4 receptor is implicated in various pathological conditions, including neuropathic pain and cancer. This study reports the development of 1,4-naphthodiazepinedione-based P2X4 receptor antagonists aimed at both therapeutic applications and potential use as PET tracers for imaging P2X4 receptor expression in cancer. Structure-activity relationship studies aided by docking studies and molecular dynamics simulations led to a series of compounds with potent P2X4 receptor antagonism, promising in vitro inhibition of interleukin-1β release in THP-1 cells and suitability for radiolabeling with fluorine-18. The most potent compounds were further evaluated for their physicochemical properties, metabolic stability, and in vivo biodistribution using PET imaging in mice. While these antagonists exhibited strong receptor binding and serum stability, rapid in vivo metabolism limited their potential as PET tracers, highlighting the need for further structural optimization. This study advances the understanding of P2X4 receptor antagonism and underscores the challenges in developing effective PET tracers for this target.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Purinergic P2X Receptor Antagonists
|2 NLM Chemicals
650 _ 7 |a Receptors, Purinergic P2X4
|2 NLM Chemicals
650 _ 7 |a Fluorine Radioisotopes
|2 NLM Chemicals
650 _ 2 |a Structure-Activity Relationship
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: methods
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Purinergic P2X Receptor Antagonists: chemistry
|2 MeSH
650 _ 2 |a Purinergic P2X Receptor Antagonists: pharmacology
|2 MeSH
650 _ 2 |a Purinergic P2X Receptor Antagonists: metabolism
|2 MeSH
650 _ 2 |a Purinergic P2X Receptor Antagonists: pharmacokinetics
|2 MeSH
650 _ 2 |a Purinergic P2X Receptor Antagonists: chemical synthesis
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Receptors, Purinergic P2X4: metabolism
|2 MeSH
650 _ 2 |a Tissue Distribution
|2 MeSH
650 _ 2 |a Fluorine Radioisotopes
|2 MeSH
650 _ 2 |a Molecular Docking Simulation
|2 MeSH
650 _ 2 |a Male
|2 MeSH
700 1 _ |a Prinz, Ann-Kathrin
|b 1
700 1 _ |a Wagner, Stefan
|b 2
700 1 _ |a Massa, Joana
|0 0000-0001-5613-5308
|b 3
700 1 _ |a Dunker, Calvin
|0 0000-0002-2109-5817
|b 4
700 1 _ |a Höhl, Meike
|b 5
700 1 _ |a Griep, Angelika
|0 P:(DE-2719)2811029
|b 6
|u dzne
700 1 _ |a McManus, Róisín M
|0 P:(DE-2719)2811671
|b 7
700 1 _ |a Schelhaas, Sonja
|0 0000-0001-6928-4847
|b 8
700 1 _ |a Koch, Oliver
|b 9
700 1 _ |a Junker, Anna
|0 0000-0001-5151-0930
|b 10
773 _ _ |a 10.1021/acs.jmedchem.4c02171
|g Vol. 68, no. 7, p. 6965 - 7002
|0 PERI:(DE-600)1491411-6
|n 7
|p 6965 - 7002
|t Journal of medicinal chemistry
|v 68
|y 2025
|x 0095-9065
856 4 _ |u https://pub.dzne.de/record/277979/files/DZNE-2025-00511%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/277979/files/DZNE-2025-00511%20SUP2.csv
856 4 _ |u https://pub.dzne.de/record/277979/files/DZNE-2025-00511.pdf
856 4 _ |u https://pub.dzne.de/record/277979/files/DZNE-2025-00511%20SUP1.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://pub.dzne.de/record/277979/files/DZNE-2025-00511.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:277979
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811029
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811671
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1200
|2 StatID
|b Chemical Reactions
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1210
|2 StatID
|b Index Chemicus
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1013024
|k AG Latz
|l Innate Immunity in Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1013042
|k AG McManus
|l Translational Neuroimmunology
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1013024
980 _ _ |a I:(DE-2719)1013042
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21